Cargando…
High Validity of the Danish National Patient Registry for Systemic Anticancer Treatment Registration from 2009 to 2019
BACKGROUND: The Danish National Patient Registry is a major resource for Danish epidemiology. Only a few studies have been conducted to check the validity of the reporting of systemic anticancer treatments. In this study, we assessed this validity for a range of cancer types over a long period of ti...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628125/ https://www.ncbi.nlm.nih.gov/pubmed/34853537 http://dx.doi.org/10.2147/CLEP.S332776 |
_version_ | 1784606955726176256 |
---|---|
author | Vesteghem, Charles Brøndum, Rasmus Froberg Falkmer, Ursula G Pottegård, Anton Poulsen, Laurids Østergaard Bøgsted, Martin |
author_facet | Vesteghem, Charles Brøndum, Rasmus Froberg Falkmer, Ursula G Pottegård, Anton Poulsen, Laurids Østergaard Bøgsted, Martin |
author_sort | Vesteghem, Charles |
collection | PubMed |
description | BACKGROUND: The Danish National Patient Registry is a major resource for Danish epidemiology. Only a few studies have been conducted to check the validity of the reporting of systemic anticancer treatments. In this study, we assessed this validity for a range of cancer types over a long period of time. PATIENTS AND METHODS: We extracted systemic anticancer treatment procedures from the Danish National Patient Registry for patients with solid malignant tumors treated at the Department of Oncology at Aalborg University Hospital between 2009 and 2019 (12,014 patients with 215,293 drug records). These data were compared to records obtained from the antineoplastic prescription database used at the department. We estimated the sensitivity, positive predictive value (PPV), and F1-score defined as the harmonic mean of the sensitivity and the PPV. RESULTS: There was an overall high concordance between the two datasets with a sensitivity and a PPV >92%. Treatments for brain, ovarian and endometrial cancers displayed lower concordance (81–89%). The validity was stable over the study period, with a slight drop during 2016–2017. Most drugs had a high validity with F1-scores above 90%. Fluorouracil, gemcitabine, pemetrexed, pembrolizumab, and nivolumab had F1-scores above 97%. Drugs that were introduced in the study period, such as lapatinib, palbociclib, erlotinib, pertuzumab, and panitumumab, yielded lower F1-scores due to the absence of specific registry codes early after introduction. CONCLUSION: The Danish National Patient Registry can be used to reliably obtain information about systemic anticancer treatments, keeping in mind limitations for recently introduced drugs and for some types of cancer. |
format | Online Article Text |
id | pubmed-8628125 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-86281252021-11-30 High Validity of the Danish National Patient Registry for Systemic Anticancer Treatment Registration from 2009 to 2019 Vesteghem, Charles Brøndum, Rasmus Froberg Falkmer, Ursula G Pottegård, Anton Poulsen, Laurids Østergaard Bøgsted, Martin Clin Epidemiol Original Research BACKGROUND: The Danish National Patient Registry is a major resource for Danish epidemiology. Only a few studies have been conducted to check the validity of the reporting of systemic anticancer treatments. In this study, we assessed this validity for a range of cancer types over a long period of time. PATIENTS AND METHODS: We extracted systemic anticancer treatment procedures from the Danish National Patient Registry for patients with solid malignant tumors treated at the Department of Oncology at Aalborg University Hospital between 2009 and 2019 (12,014 patients with 215,293 drug records). These data were compared to records obtained from the antineoplastic prescription database used at the department. We estimated the sensitivity, positive predictive value (PPV), and F1-score defined as the harmonic mean of the sensitivity and the PPV. RESULTS: There was an overall high concordance between the two datasets with a sensitivity and a PPV >92%. Treatments for brain, ovarian and endometrial cancers displayed lower concordance (81–89%). The validity was stable over the study period, with a slight drop during 2016–2017. Most drugs had a high validity with F1-scores above 90%. Fluorouracil, gemcitabine, pemetrexed, pembrolizumab, and nivolumab had F1-scores above 97%. Drugs that were introduced in the study period, such as lapatinib, palbociclib, erlotinib, pertuzumab, and panitumumab, yielded lower F1-scores due to the absence of specific registry codes early after introduction. CONCLUSION: The Danish National Patient Registry can be used to reliably obtain information about systemic anticancer treatments, keeping in mind limitations for recently introduced drugs and for some types of cancer. Dove 2021-11-24 /pmc/articles/PMC8628125/ /pubmed/34853537 http://dx.doi.org/10.2147/CLEP.S332776 Text en © 2021 Vesteghem et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Vesteghem, Charles Brøndum, Rasmus Froberg Falkmer, Ursula G Pottegård, Anton Poulsen, Laurids Østergaard Bøgsted, Martin High Validity of the Danish National Patient Registry for Systemic Anticancer Treatment Registration from 2009 to 2019 |
title | High Validity of the Danish National Patient Registry for Systemic Anticancer Treatment Registration from 2009 to 2019 |
title_full | High Validity of the Danish National Patient Registry for Systemic Anticancer Treatment Registration from 2009 to 2019 |
title_fullStr | High Validity of the Danish National Patient Registry for Systemic Anticancer Treatment Registration from 2009 to 2019 |
title_full_unstemmed | High Validity of the Danish National Patient Registry for Systemic Anticancer Treatment Registration from 2009 to 2019 |
title_short | High Validity of the Danish National Patient Registry for Systemic Anticancer Treatment Registration from 2009 to 2019 |
title_sort | high validity of the danish national patient registry for systemic anticancer treatment registration from 2009 to 2019 |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628125/ https://www.ncbi.nlm.nih.gov/pubmed/34853537 http://dx.doi.org/10.2147/CLEP.S332776 |
work_keys_str_mv | AT vesteghemcharles highvalidityofthedanishnationalpatientregistryforsystemicanticancertreatmentregistrationfrom2009to2019 AT brøndumrasmusfroberg highvalidityofthedanishnationalpatientregistryforsystemicanticancertreatmentregistrationfrom2009to2019 AT falkmerursulag highvalidityofthedanishnationalpatientregistryforsystemicanticancertreatmentregistrationfrom2009to2019 AT pottegardanton highvalidityofthedanishnationalpatientregistryforsystemicanticancertreatmentregistrationfrom2009to2019 AT poulsenlauridsøstergaard highvalidityofthedanishnationalpatientregistryforsystemicanticancertreatmentregistrationfrom2009to2019 AT bøgstedmartin highvalidityofthedanishnationalpatientregistryforsystemicanticancertreatmentregistrationfrom2009to2019 |